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Introduction
The abnormal assembly of proteins is implicated in over 
30 human disorders, which include Alzheimer’s disease (Aβ1–
42), Parkinson’s disease (α-synuclein), and dialysis related am-
yloidosis  (β2-microglobulin).1–4 Alzheimer’s disease (AD) is 
perhaps best characterized by the extracellular deposits of the 
39–42 amino acid amyloid-β peptides (Aβ) along with neurofi-
brillary tangles in the brains of patients. Aβ peptides arise from 
cleavage of the extracellular portion of the transmembrane 
amyloid-precursor  protein  (APP)  by  β-  and  γ-secretases.5–7 
The elucidation of the genetic, biochemical, and biophysical 
origins of Alzheimer’s disease (AD) remains a complex and 
formidable  challenge.  The  toxicity  of  processed  Aβ  peptide 
may include a combination of apoptosis,8 disrupted Ca2+ ho-
meostasis,9 toxic radicals,10, 11 and complement formation.12 
Over the past decade Selkoe,13 Lansbury,14 Teplow,15 Kelly,4 
Dobson,16, 17 and Prusiner,18 among many others have helped 
establish  a  general  nucleation  dependent  paradigm  for  fibril 
formation (Figure 1). These ongoing experiments have also 
demonstrated that the rate of fibrillization and the morphology 
of the final fibrillar state are strongly influenced by environmen-
tal factors (pH, salt, temperature, agitation, etc.); chemicals 
(proteins, lipids, cholesterol, metals, etc.); and by the nature 
of the seeding agent.14 In the case of Aβ, evidence from both 
in vitro19, 20 and in vivo21, 22 studies strongly suggest that solu-
ble oligomeric Aβ forms with β-sheet secondary structure are 
responsible for neurological toxicity (Figure 1).22, 23 In this re-
view we will briefly present current structural paradigms in AD 
followed by a discussion of the molecular approaches towards 
targeting oligomers and fibrils.
The presence of amyloid plaque in the postmortem brains 
of patients suffering from Alzheimer’s disease led to the hy-
pothesis that these extracellular plaques were pathological to 
the  neuronal  cells.  This  view was  further  confirmed  by  in vi-
tro experiments where Aβ fibrils upon  incubation with rat hip-
pocampal cultures were found to be toxic to these neuronal 
cells.24–26 However, much current work with amyloidogenic 
proteins has led to a paradigm shift towards an oligomeric 
toxic species. The evidence for a toxic oligomeric intermedi-
ate rests on the following experiments: firstly,  there seems to 
be a stronger correlation between “soluble Aβ” (monomer and 
oligomers of Aβ)  in  the brain  and early  cognitive dysfunction 
than there  is between the Aβ deposits and clinical severity of 
AD;27–30 secondly, transgenic mice that overexpress APP ex-
hibited neuronal and behavioral abnormalities before amyloid 
plaques were detected31, 32 and thirdly, soluble oligomers of Aβ 
were found to be toxic to cell cultures33, 34 and affected hip-
pocampal long term potentiation when injected in transgenic 
mice.21, 35 Haass & Selkoe  have  also  argued  that Aβ  aggre-
gates present less surface area for interaction with the neu-
rons as compared to the soluble intermediates which can eas-
ily diffuse into synaptic clefts and hence are better candidates 
for causing neuronal dysfunction.36 Several of these intermedi-
ates have been validated in aggregation studies of purified Aβ, 
whereas some have also been isolated and purified from cell 
cultures and brains of transgenic mice (Table 1).
Interestingly, studies in the similar Huntington’s Disease, 
showed  significantly  less  cell  death when  fibrils  of  polygluta-
mine oligomers of the huntingtin protein were present.37, 38 
This has led many researchers to postulate that in some cases 
the fibrillar aggregates may protect normal cells against  toxic 
oligomeric intermediates.39, 40 However, deposits of Aβ  in AD 
brain do show surrounding dystrophic neuritis indicating that 
insoluble aggregates may be contributing to neuronal injury.41 
It is also possible that the large aggregates are in slow equilib-
rium with surrounding soluble oligomers which may be the ac-
tual toxic species (Figure 1). Although, it is not clear that oligo-
mers  lie  in  the  same  pathway  as  fibrils  as  small  molecules 
which  inhibit  oligomer  formation  but  not  fibril  formation  have  
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been described.42 Hence at the current time the true culprit in 
these diseases, whether  fibrillar or oligomeric,  remains  to be 
unequivocally established. Studies on model protein aggre-
gates are also aiding in this effort.16, 43–47 Many experiments 
are underway to provide a molecular level understanding of 
the Aβ oligomers and the data are summarized in Table 1. This 
data clearly suggests that even the actual dimensions of these 
oligomers, whether 2 nm, 20 nm, or even micellar, still remains 
to be established. The data presently suggest that it is very 
likely  that multiple oligomeric species are  implicated  in  the fi-
brillization pathway.
In comparison to our understanding of the oligomers, ongo-
ing solid state NMR studies from Tycko are rapidly unraveling 
a true molecular description of the Aβ1–40 fibrils. Current work 
suggests that the amyloid structure favors a C2z symmetry
48 
that is primarily stabilized by hydrophobic interactions involv-




arate layers of Aβ molecules) (Figure 2).49 Salt bridges formed 
between K28 and D23 also appear to be important for stability, 
as a lactam crosslink between K28 and D23 has been shown 
to  delay  fibrillization.50  Once  formed,  the  fibril  structure may 
exclude water as significant changes in structure were not ob-
served when water was removed by freeze-drying. In contrast 
to some earlier models, Tycko has proposed that native amy-
loid fibrils are more commonly composed of parallel β-sheets 
whereas the antiparallel arrangement may be predominant in 
fibrils formed from short peptides.49 Emerging models of poly-
glutamine fibrils may also illuminate this issue.51
Further biophysical characterization of these intermedi-
ates will allow for a structure guided discussion of how differ-
ent known ligands interact with Aβ and provide a rational tem-
plate for either stabilizing or disrupting these oligomers. It is 
perhaps possible that the ligands that target specific oligomers 
of Aβ will  provide  a method  for  trapping  these  intermediates 
for structural elucidation. The following discussion will entail 
a  review of amyloid  (oligomeric or fibrillar) binding molecules 
and new molecular approaches for preventing Aβ aggregation 
and toxicity, which has been the focus of most studies to date. 
Our review is divided into the following five sections: 1) Natu-
Figure 1. Model for the fibrillogenesis pathway for Aβ.13–18
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ronment is still not clearly understood, numerous experiments 
have been conducted to determine possible natural protein 
binding partners of Aβ. Some of these natural ligands may be 
a missing  link  between Aβ  accumulation  and  cellular  toxicity 
(Table 2). A few of these interacting proteins which have been 
studied in greater detail are discussed below.
The conventional yeast two-hybrid system, used to detect 
protein–protein  interactions  in vivo, has been applied  to Aβ.57 
This system was able  to specifically  report on  the  interaction 
of Aβ monomers  in  the  yeast  nucleus. A  control  bait  protein 
which contained double Phe to Thr substitutions, at residues 
19 and 20 of the hydrophobic core, did not produce apprecia-
ble  signal,  indicating  that  the  observed Aβ  interactions  were 
likely specific.
Subsequently a similar yeast two-hybrid system was also 
used to identify an endoplasmic-reticulum associated binding 






crystal structure shows that the active site is severely per-
turbed such that NAD binding is prevented. An ABAD derived 
peptide was shown  to suppress Aβ  toxicity while  the overex-
pression of ABAD in the presence of Aβ led to an increase in 
oxidative stress in transgenic mice. An ELISA based screen 
has identified small molecule  inhibitors of  the Aβ-ABAD inter-
action.60 The most potent of these inhibitors had an IC50 value 
of <10 μM but  its ability  to decrease the cytotoxicity of Aβ re-
mains to be demonstrated.
The early observations of increased phosphorylation of pro-
teins in Alzheimer’s patients led to the hypothesis that Aβ may 
directly perturb the activities of certain kinases. Indeed, the ac-
Table 1. Oligomers of Aβ.
Aβ oligomers  Characteristic feature  Method of preparation  Ref.
SDS stable Aβ   These oligomers are resistant to SDS and protease  SDS stable dimer and trimers of Aβ1–40 were 52,
 53 
dimers and  (insulin-degrading enzyme, IDE). They were found detected in cellular media of Chinese hamster 
trimers to affect synaptic structure and function. ovary cells which were transfected with the  
    APP gene to overexpress Aβ. 
       
Protofibrils  Curvilinear, metastable intermediates which disappear   Aβ1–40 (500 μM) upon incubation in phosphate  12,
 16, 42, 43 
  as fibrils are formed, usually 4-10 nm diameter and up   buffer, pH 7.4 at room temperature for 1–2 days  
  to 200 nm in length; have been shown to cause   showed equivalent amounts of protofibrils and  
  decrease in levels of reduced MTT in rat neuronal   low molecular weight oligomers; Aβ1–40 (50 μM) 
 culture. when incubated with calmidazolium chloride  
    (100 μM) for 2 days predominantly formed protofibrils. 
       
Annular   Doughnut like structures with inner diameter of   The arctic mutant of Aβ1–40 (E22G) formed  54,
 55 
assemblies 2.0–2.5 nm and outer diameter of 8–12 nm. annular intermediate species more rapidly and  
  to a greater extent as compared to the wild type  
    Aβ. These were separated by SEC. Low molecular  
    weight oligomers of Aβ1–42 fractionated by SEC  
  consisted of pentamers/hexamers and formed  
  beaded structures. 
       
Amylospheroids   Spherical oligomers of 3–20 nm in diameter  Aβ1–40 (350 μM) when rotated slowly using a   34 
(ASPD)  observed in aggregating samples of both Aβ1–40  rotating cultivator at 37
 °C for 5–7 days, formed 
  and Aβ1–42. Spheroids of size 10–15 nm were   ASPDs. Aβ42 ASPDs were prepared by rotating 
 toxic to primary cultures of neuronal cells from  the samples at 4 °C for 8–10 h. 
 rat brain. ASPDs of size <10 nm were non-toxic.    
       
Aβ-derived   Globular intermediates (5–6 nm in diameter),   ADDLs of Aβ1–42 have been prepared by 23,
 33 
diffusible   smaller than the annular assemblies. These have  incubating Aβ with clusterin for 24 h. In 
ligands   been shown to kill mature neurons at nanomolar  clusterin-free solution, ADDLs of Aβ were prepared 
(ADDLs)  concentrations. Also evoked neurological   by incubating a 100 μM solution of Aβ1–42 at 4–8
 °C 
  dysfunctions well before cellular degeneration.  for 24 h or by diluting an Aβ solution to 50 nM at  
  37 °C. However, preparation of these species may  
    be dependant on specific conditions such as the use  
  of DMEM-F12 media (without phenol red) and the  
  lack of agitation during incubation. 
       
Aβ*56  Dodecameric assembly of Aβ1–42 extracted and purified   Aβ*56 was separated by a high-fidelity extraction  56 
 from extra-cellular fraction from 6 month old transgenic  procedure that separated protein into extra-cellular,  
  mice. Aβ*56 disrupted memory when administered to   intra-cellular, membrane enriched and insoluble 
 young rats. fractions. 
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tivities of purified casein kinase I and II (CKI and II) have been 
shown to be increased in a concentration dependent manner 
by Aβ when monitoring  phosphorylation  of  casein.61 Overex-
pression of a constituently active form of CKI has been shown 
to increase the amount of Aβ in brain tissue cultures.86 Three 
different  CKI-specific  inhibitors  were  shown  to  decrease  the 
amount  of Aβ  produced. This  approach  has  the  potential  for 
identifying novel therapeutics for the treatment of Alzheimer’s 
if  the CKI/Aβ  interaction correlates with cognitive  failure.  It  is 
still to be established whether the observed effects are directly 
or indirectly mediated by Aβ in a physiological context.
The activity-dependent neuroprotective protein (ADNP) 
was discovered by screening cDNA libraries by antibody mat-
uration. A very short eight amino-acid segment of this protein, 
NAPVSIPQ, was shown to protect neuronal cells against Aβ at 
femtomolar concentrations.63, 87 A study has shown that intra-
nasal administration of this peptide can significantly reduce the 
levels of Aβ in transgenic mice model of Alzheimer’s.9 Again it 
is very possible that this peptide does not function by direct in-
teraction with Aβ.
Transthyretin, a protein  in  the cerebral  fluid, was  found  to 
bind  to  Aβ  through  fractionation  of  an  Aβ-binding  activity.85 
Subsequently, transgenic mice containing a mutation in the 
APP gene predisposing them to early onset AD, the Swiss mu-
tation, were found to overexpress transthyretin.88 This overex-
pression correlated with a decrease in the progression of AD 
Figure 2. Structural model for the protofilament in Aβ1–40 fibrils prepared with gentle agitation a) All-atom representation of a pair of peptide mol-
ecules. Residues 10–22 and 30–40 have β-strand conformations, forming two separate in-register, parallel β-sheets. The protofilament is a four-
layered β-sheet structure with C2 symmetry about its long axis. Double-headed arrows indicate side chain–side chain and side chain–backbone 
contacts established by 2D 13C-13C NMR measurements or 15N-13C dipole-dipole couplings. b) Average structure resulting from ten independent 
molecular dynamics/energy minimizations runs on a cluster of twelve peptides, with interatomic distance and backbone torsion angle restraints 
dictated by solid-state NMR data. The four-layered β-sheet structure  is stabilized primarily by hydrophobic  interactions in the core of the proto-
filament. Polar and charged side-chains are on the exterior, with the exception of oppositely charged K28 and D23 side-chains, which form salt 
bridges. c) and d) Cartoon representations with residues 12–21 and 30–40 shaded. (Reprinted with permission from Cambridge University Press)
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symptoms such that disease onset was delayed. Forty-seven 
individual point mutants of transthyretin have been analyzed 
for Aβ-binding  and  inhibition  of  fibril  formation.89 All but two 
mutants,  G42  and  P55,  bound Aβ,  localizing  the Aβ-binding 
activity to this region. Studies suggest that transthyretin de-
creases the rate of fibril formation by decreasing the lateral as-
sociation of fibrils as well as decreasing the rate of elongation 
of fibrils.90 These data would indicate that, at concentrations of 
2 μM transthyretin and 140 μM Aβ, transthyretin binds to the fi-
brillar form of Aβ arresting the formation of plaques. This study 
is quite interesting, given that transthyretin itself is directly im-
plicated in a different misfolding disease and one of the few in-
stances where small molecules are known to inhibit aggrega-
tion by stabilizing the native state.91
From the above studies with possible natural protein li-
gands of Aβ, it is clear that there are many possible candidate 
proteins  that directly or  indirectly  interact with Aβ and modu-
late its activity. With a growing list of candidate proteins the 
physiological  role of Aβ will  likely be established,  resulting  in 
new methods for diagnosing and possibly treating AD. Struc-
tural details of true and potent Aβ bound complexes will likely 
provide the necessary molecular templates for the design of 




Several elegant strategies have been used to rationally de-
sign peptidic  inhibitors of Aβ aggregation, some of which are 
discussed in detail (Table 3). Many of these approaches rely 
on using fragments of the parent Aβ sequence as recognition 
elements  in  a  dominant  negative  fashion. Typically,  fibril  dis-
rupting  chemical  elements  are  incorporated  into  Aβ  derived 
peptides  in  the  form  of  N-  or  C-terminal  modifications,  con-
formationally constrained amino acids, or modifications to the 
peptide backbone. These concepts have also been applied to 
D-amino acid variants of the parent Aβ sequence. These differ-
ent molecular design strategies are discussed below.
N- and C-terminal modifications
Inhibitors  of  fibril  formation  based  on  the  hydrophobic  re-
gion  of  Aβ  are  the  most  prevalent.  Initial  work  in  this  area 
identified  the KLVFF motif92 as capable of  inhibiting fibril  for-
mation. A variant of this core domain (Table 3 a) contain-
ing a polycationic disrupting region appended to the C ter-
minus, KLVFFKKKKKK, was shown to increase the rate of 
fibril  formation  and  cell  viability.93, 94  The  rate  of  fibril  forma-
Table 2. Biomolecules that bind Aβ.
Biomolecule Method of Discovery/Evidence Ref.
Aβ-Binding Alcohol Dehydrogenase  Yeast two-hybrid screen using a human brain cDNA library  58
Aβ-Related Death-Inducing Protein  Yeast two-hybrid screen using a human brain cDNA library  62
Activity-Dependent Neuroprotective  Isolated from a cDNA library from mouse embryonic carcinoma cells 63 
    Protein      induced to differentiate into neurons using retinoic acid 
α1-Antichymotrypsin Antigen maturation of a cDNA library 64
α-7 Nicotinic Acetylcholine Receptor  Co-immunoprecipitation from human brain tissue  65
α-Ketoglutarate  Enzyme activity in isolated rat brain mitochondria  66
β2-Macroglobin Yeast two-hybrid screen using a HeLa cDNA library 67
Amyloid Precursor Protein  Co-precipitation with Aβ in rat hippocampal cultures  8
Apolipoprotein E4 Amyloid deposition in a mice model correlated to Apo E4 expression 68, 69
Apolipoprotein J  Affinity purification from cerebral spinal fluid by immobilized Aβ  70
Casein Kinase I and II In vitro phosphorylation assay using casein 61
Catalase In vitro binding assay to monitor catalase binding 71
Collagen-like Alzheimer Amyloid Plaque   Isolation of an Aβ-associated antigen further fractionation and identification  72 
    Component     using proteolytic cleavage and protein sequencing 
Cytochrome Oxidase Enzyme activity in isolated rat brain mitochondria 66
Formyl Peptide Receptor Like-1 Chemotaxis of monocytes and Ca2+ mobilization 73
Gelsolin  ELISA assay for Aβ-binding to immobilized gelsolin  74
Heat Shock Proteins 70 and 90 In vitro inhibition of Aβ assembly  75




Protein Kinase C Tissue culture phosphorylation assay 80
Pyruvate Dehydrogenase Enzyme activity in isolated rat brain mitochondria 66
Receptor for Advanced Glycation End   Isolation of a Aβ-binding activity and protein sequencing  81 
    Products  








Peptide  Activity  Structure  Ref.
KLVFF  Inhibited fibril formation  KLVFF  92
KLVFFKKKKKK Kd: 40 μM, SPR  KLVFFKKKKKK  94
KLVFFKKKK Kd: 37 μM, SPR  KLVFFKKKK  94
KLVFFKK Kd: 80 μM, SPR  KLVFFKK  94
KLVFFEEEKKK Kd: 1.3 mM, SPR KLVFFEEEKKK 94
KKKKLVFF Kd: 180 μM, SPR  KKKKLVFF  94
DDX3 Reduced toxicity in neuroblastoma cells  101
RIIGL  Inhibited fibril formation and toxicity  RIIGL  95
PrIIGL Was toxic in cellular assays PrIIGL 95
       
b) Conformationally Constrained Peptides:
Peptide Activity Structure Ref.
iAβ5  Inhibited fibril formation, disassembled fibrils,   LPFFD  96 
     and reduced toxicity 
AMY-1  No fibril formation after 4.5 months    97
AMY-2  Rapid formation of large nonfibrillar aggregates    97
       
c) Backbone Modifications:
Peptide Activity Structure Ref.
Aβ16–22m  IC50: 420 μM using ThT  KNMeLVNMeFFNMeAE 98
NMeGly25 Similar to parent sequence NMeGSNKGAIIGLM 99
NMeGly33  Inhibited fibril formation and reduced toxicity  GSNKGAIINMeGLM 99
NMeLeu34  Altered fibril morphology  GSNKGAIIGNMeLM 99
Aβ16–20e  Inhibits fibril formation and disassembles fibrils    100
       
d) d-Amino Acid Peptides:
Peptide Activity Structure Ref.
SEN 301  Produced multiple types of fibrils    102
SEN 302 Least effective at reducing toxicity  102
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tion increased with the number of lysine residues as follows: 
KLVFFKK<KLVFFKKKK<KLVFFKKKKKK. The effect of charge 
distribution and the orientation of the disrupting element was 
also  verified  using  KLVFFEEEKKK  and  KKKKLVFF.  Both  of 
these peptides bound with less affinity to Aβ as determined by 
SPR. The ability of these peptides to accelerate fibril formation 
while decreasing toxicity is very intriguing, and suggests that 
the new fibrils are not toxic or that they are no longer in equi-
librium with the toxic oligomeric intermediates. A peptide cor-
responding  to Aβ31–34 when appended to a N-terminal propi-
onyl group (PrIIGL)
95 was shown to  form fibers and was toxic 
to neuroblastoma cells. However, replacement of the propio-
nyl group with an arginine (RIIGL) resulted in a peptide which 
inhibited  fibril  formation  and  reduced  toxicity  of Aβ,  possibly 
sequestering the toxic oligomeric species and preventing in-
teractions at the cell membrane. The above studies are quite 
significant as they suggest multiple new routes to interfere with 
Aβ assembly and may also be starting points for designing re-
agents that trap and stabilize intermediates that can be further 
studied at the molecular level.
Conformationally constrained peptides
Building on the observation that the hydrophobic core of 




bril formation through unfavorable steric interactions or al-
ternatively  by  redirecting  Aβ  assembly  in  alternate  nontoxic 
arrangements.  This  peptide  was  reported  to  disassemble  fi-
brils in vitro and to increase cell viability.
A new class of conformationally constrained peptides which 
contained α,α-disubstituted amino acids (Table 3 b) have been 
synthesized.97  These  α,α-disubstituted  amino  acids  were  in-
corporated in such a way that one face of the peptide would 
be sterically blocked. The peptide AMY-1 was shown to abro-
gate fibril formation for up to 4.5 months, whereas AMY-2 was 
shown to produce nonfibrillar aggregates. The authors suggest 
that this difference in activity may be attributed to the position-
ing of the hydrophilic tails in each peptide, such that the polyly-
Table 3. Designed peptide inhibitors of Aβ (continued).
Aβ(1–42): DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
SEN 303  Significantly reduced toxicity    102
SEN 304  Significantly reduced toxicity    102
SEN 305 Reduced toxicity to a lesser extent  102
SEN 306 Reduced toxicity to a lesser extent  102
SEN 307 Reduced toxicity to a lesser extent  102
D-KLVFF  Inhibited fibril formation  D-KLVFF  103
PPI-433  Inhibited fibril formation and reduced toxicity    104
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sine tail at the C terminus disrupts amyloid aggregation by in-
terfering with committed assembly steps within the N-terminal 
hydrophobic region.
Another  interesting  approach  in  this  area  of Aβ  mimetics 
is the substitution of alternating amide hydrogens with methyl 
groups (Table 3 c). This approach in principle serves to cap 
oligomeric domains and prevent the β-sheet propagation nec-
essary  for  Aβ  fibrillization.  Furthermore,  these  N-methylated 
peptides tend to have increased solubility (by preventing self 
aggregation), increased resistance to proteolytic degradation, 
and the possibility for increased blood-brain barrier penetra-
tion. Meredith and co-workers designed inhibitors based on the 
much studied hydrophobic core Aβ motif KLVFFAE, containing 
N-methylated amino acids.98 These peptides were found to in-
hibit  fibril  formation  and  disassemble  preformed  fibrils  in vi-
tro. The most potent inhibitor contained alternating sites of N-
methylation,  Aβ16-22m.  N-methylated  Aβ  derived  peptides 
have  also  been  reported  by  Doig  based  on Aβ25–35 (GSNK-
GAIIGLM).99 The authors showed that NMeGly25 had no ac-
tivity and actually showed similar aggregation and toxicity lev-
els as that of the wild-type sequence. However, NMeGly33 was 
shown  to  completely  inhibit  fibril  formation,  disassemble  pre-
formed fibrils, and reduce cellular toxicity. These results would 
imply  that  the position of N-methylation  is  crucial  for efficacy 
and likely maps to a critical region of the growing amyloid fibril 
(Table 3). Meredith and co-workers have also investigated the 
effect of replacing the amide backbone with ester bond surro-
gates at alternating positions.100 The peptide, Aβ16-20e, was 
synthesized and shown to inhibit fibril formation and disassem-
ble fibrils in vitro. This ester containing peptide likely functions 
by preventing hydrogen-bond propagation as seen in the alter-
nating N-methylation approach. What is also very interesting 
is  the  reported disassembly of pre-existing fibers, which may 




Doig and coworkers systematically explored the struc-
ture–activity relationship of numerous peptides based on 
the KLVFFA sequence.102 The initial library of KLVFFA pep-
tides revealed that peptides containing the core LVFFL mo-
tif were  the most  effective  at  inhibiting  fibrillization. Efficacy 
was increased when peptides were constructed entirely from 
D-amino acids and singly methylated at the first and fifth po-
sitions or doubly methylated at both positions. Using this in-
formation the authors developed four new libraries to ascer-
tain the effects of the position of N-methylation and amino 
acid preference. The authors found that large branched hy-
drophobic side chains were preferred at positions 1–4 and 
that  a  single  N-methylated  site  was  sufficient  for  fibril  in-
hibition.  All  peptides  from  this  final  compound  library  were 
shown to decrease toxicity in PC12 cells using the MTT as-
say. The most potent compound, SEN 304, was determined 
to be more active than the β-sheet breaker peptide96 as de-
termined by ThT and MTT assays.
Other interesting approaches105  have  targeted  Aβ  utiliz-
ing peptides based on the GxFxGxF scaffold expected to in-
teract with the C terminus of Aβ. The most active compound 
RGTWEGKW  was  shown  to  inhibit  fibril  formation  and  re-
duce cellular toxicity. The authors propose that alternat-
ing hydrophilic-hydrophobic nature of this peptide may help 
to  disrupt Aβ  aggregation. A  different  approach  has  utilized 
the so-called surface tension-modifying peptides106 that ac-
tually  increased the rate of Aβ fibril  formation several-fold.  It 
remains to be seen if such peptides prevent the build up of 
the  toxic soluble  intermediates by sequestering Aβ  in  the fi-
bril state.
Thus, it is clear that the considerable efforts in the rational 
design of Aβ-targeting molecules based on the parent Aβ se-
quence have been quite fruitful in providing a large class of 
compounds with different modes of activity.107 These peptido-
mimetic molecules by themselves or with further modifications 
provide a class of reagents that may help elucidate the mech-
anism of amyloid aggregation, perhaps by trapping intermedi-
ates, as well as providing inroads into the design of diagnostic 
and therapeutic reagents.
3. Targeting Aβ with Antibodies
Antibodies,  because  of  their  specificity  and  conformation 
dependence, have been attractive choices for potential ther-
apeutic strategies for the treatment of AD. They are now also 
being used  to distinguish between fibrils and prefibrillar  inter-
mediates in the aggregation pathway. The recent develop-
ments in Aβ immunotherapy and in the use of site-directed an-
tibodies as tools for understanding the amyloid aggregation 
pathway is elaborated in the following two subsections:
Aβ Immunotherapy
Antibodies generated against Aβ1–42 were shown to lower 
cerebral amyloid plaques in mouse models.108 However, a 
clinical  trial  using  Aβ1–42  fibrils  for  active  immunization  was 
halted when ~6 % of the patients developed meningoencepha-
litis,109, 110 possibly due to a potent T-cell mediated immune re-
sponse. To avoid the risk of such an adverse autoimmune re-
sponse and to develop safer vaccines, newer strategies are 
being tested in Aβ immunotherapy using the N terminus Aβ1–15 
fragment which has been demonstrated to lack T-cell reactiv-
ity in mice and humans.111, 112 As a monovalent linear peptide 
would not be an effective immunogen, Agadjanyan et al. syn-
thesized the Aβ1–15 fragment in tandem with an HLA DR bind-
ing peptide (PADRE).113 PADRE is a 13-residue nonnatural 
peptide that is a potent T-cell epitope. PADRE-Aβ1–15 was syn-
thesized on a multiple antigenic peptide (MAP) platform to en-
hance the immune response by a multivalent effect. Antibod-
ies  induced  by  PADRE-Aβ1–15-MAP  were  specific  to Aβ  and 
did not bind to the MAP backbone or PADRE. These antibod-
ies  prevented Aβ  fibrillization  and  the  splenocytes  from mice 
showed T-cell stimulation only to PADRE and not to Aβ T-cell 
epitopes. In a similar approach, bacterial thioredoxin (Trx) was 
used as a scaffold to link four repeats of Aβ1–15.
114 The anti-Trx 
(Aβ15)4 antibody generated against this epitope bound to Aβ1–
42 fibrils and oligomers but not monomers and reduced Aβ pa-
thology in transgenic AD mice.
In a complementary approach, Maier et al. have tested pep-
tide immunogens consisting of tandem repeats of di-lysine 
linked Aβ1–15 sequences (Aβ1–15-KK-Aβ1–15) and found them to 
be more effective in boosting the immune response as com-




genic AD mice without splenocyte proliferation.115 Animals 
immunized  with Aβ1–15-KK-Aβ1–15 also showed improved ac-
quisition of memory as compared to the controls. Thus, these 
new studies using active immunization show much promise 
but will ultimately have  to demonstrate safety and efficacy  in 
clinical trials. It would also be interesting to pursue the in vitro 
study of the individual antibodies elicited by these active im-
munization regimes and clearly establish the molecular mech-
anism for their interactions with Aβ.
Antibodies as probes of Aβ intermediates
Antibodies are also emerging as useful chemical probes 
for delineating the steps in Aβ assembly. As mentioned earlier, 
many reports suggest the soluble oligomers and not the fibrils 
are the toxic species,13 thus the interaction of specific antibod-
ies with Aβ are being used to directly probe such intermediate 
species for a better understanding of the aggregation pathway. 
O’Nuallain and Wetzel described the generation of two confor-
mation-specific antibodies, WO1 and WO2 that bound to Aβ1–
40  fibrils but not  soluble Aβ species, even  in  the presence of 
a large excess of Aβ1–40 monomers.
116 These antibodies were 
also able to bind amyloid fibrils of other proteins, which again 
strongly suggests  that  the final fibrillar  form of Aβ  is common 
to numerous proteins that  form fibers. To generate polyclonal 
antibodies  against  the  so-called Aβ-derived  diffusible  ligands 
(ADDLs),  the toxic soluble oligomers of Aβ1–42, Lambert et al. 
incubated Aβ solution for 48 h at 4 °C, centrifuged at 14 000 g 
for 10 min, and used the supernatant (0.24 mg Aβ mL−1) as an 
immunogen.117  This  supernatant  (defined  as ADDL  prepara-
tion) was free of amyloid fibrils and contained a mixed popula-
tion of spherical oligomers and monomers of Aβ (as observed 
by AFM). The antibodies produced recognized trimers, tetra-
mers, and surprisingly also fibrils of Aβ1–42 in dot-blot assays. 
At higher concentrations the antibody was also found to bind 
monomers. A more specific antibody probe against such oligo-
mers was prepared in a controlled fashion by Kayed et al.118 
They reacted gold nanoparticles with a C-terminal thioester 
containing Aβ1–40  to synthesize micellar mimetics of Aβ oligo-
mers (Figure 3). These micellar mimetics were similar in size 
when compared to the soluble intermediates and were used 
to immunize rabbits. The anti-oligomer antibody generated did 
not react with monomers or fibrils of Aβ1–40, but was reported 
to exclusively precipitate Aβ1–40 oligomers in dot-blot assays. 
The smallest oligomeric species recognized by this antibody 
had an apparent molecular weight of 40 kDa on size exclusion 
chromatography, which corresponds  to an octamer of Aβ1–40. 
The anti-oligomer antibody is now commercially available from 
Invitrogen and is being utilized to delineate the mechanism of 
small molecules that influence Aβ oligomerization, which is dis-
cussed in Section 5 of this review.42 Again, it is surprising that 
this new anti-oligomer antibody also recognized soluble inter-
mediates of other amyloidogenic proteins and peptides. These 
results in conjunction with the Aβ fibril targeting antibody sug-
gest that not only are the final fibrillar structures similar for dif-
ferent proteins but so are many of the intermediates.
4. Targeting Amyloid with in vitro Selected Peptides and 
Proteins
Though  antibodies  are  clearly  the  first  established  choice 
for targeting proteins and peptides, phage displayed peptides 
and protein scaffolds have also emerged as an alternate route 
for  targeting  Aβ.119, 120 Phage display approaches generally 
enrich for an immobilized protein of interest and a complicated 
Figure 3. Production of antibodies that specifically bind Aβ1–40 oligomers. In the dot blot assay, anti-oligomer antibody (A11) binds only to (1) the 
oligomeric intermediate of Aβ40 and does not show reactivity against (2) Aβ40 fibrils or (3) Aβ40 monomers, whereas 6E10 recognized all species of 
Aβ.
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immunization protocol is not necessary. Results in this area 
are tabulated (Table 4) and discussed in this section.
In one of the earliest studies in this area, a library of 20 
residue peptides was used  to  select  for Aβ1–40 binding using 
phage display.121 Only  two peptides were  identified  from  this 
selection and were shown to be capable of staining Aβ depos-
its. The sequences suggested an aromatic rich motif: (W/F)
X5(W/F)X2/3(W/F) which sometimes contained proline residues 
suggesting a turn conformation.
Mirror-image phage display allowing for the eventual iden-
tification of D-amino acid peptides (Figure 4) has been utilized 
for the discovery of peptides which bind Aβ.125 In this strategy 
a synthetic D-amino acid version (enantiomer) of the target is 
immobilized, against which a library containing L-amino acid 
peptides is selected. Once L-amino acid binders are identified, 
their D-enantiomers are synthesized and interrogated for bind-
ing to the L-amino acid target. This is an elegant approach for 
the development of peptide inhibitors that are resistant to pro-
teolytic cleavage. Using this approach Wiesehen and co-work-
ers immobilized the full length D-enantiomer of Aβ1–42 and se-
lected binders from a phage-displayed peptide library.122 The 
D-enantiomer of the most prevalent sequence from this selec-
tion, D-QSHYRHISPAQV, binds the natural L-enantiomer of 
Aβ  (1–42) with an apparent dissociation constant of 400 nM, 
though the stoichiometry of the complex remains to be ex-
plored in detail. Appropriately labeled analogues of this pep-
tide were also shown to be effective in staining Aβ deposits in 
brain tissues. However, the effect of this peptide on Aβ aggre-
gation has not been determined to date.
Phage display using the KLVFF core motif was used to 
identify peptides which bound different species  in  the Aβ ag-
gregation pathway.123 Two libraries were used to assess the 
effect of polar residues on binding and the sequence require-
ments of the core motif. Both libraries were screened against 
aggregated and monomeric Aβ. Surprisingly, peptides selected 
for binding to the monomeric species did not effect the aggre-
gation rate whereas those selected for binding to the aggre-
gated species did. The ability of these peptides to promote 
aggregation correlated with their relative affinities for the N ter-
minus  of Aβ. The  observation  that  peptides  can  be  selected 
to bind specifically  to different  intermediates  in  the Aβ aggre-
gation pathway opens up the possibility of producing tracta-
ble reagents for deciphering amyloid aggregation kinetics and 
thermodynamics.
We have recently utilized phage display to isolate variants 
of a small β-sheet scaffold126 that likely binds to intermediates 
in the aggregation pathway of Aβ.124 In this selection scheme 
(Figure 5) a phage-displayed library containing eight ran-
domized  residues on  the first  two β-strands of  the small  IgG 












Figure 4. The general scheme for selecting mirror image peptides is shown.
Figure 5. Selection of β-sheet displaying small proteins (HTB1 variants) which bind Aβ. Eight positions on two β-sheets are randomized. An initial 
structural selection, using the helical face, against IgG maintains the native fold. Subsequent rounds of selection for Aβ-binding, using the β-sheet 
face, yielded the TJ10 variant.
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enriched for proteins that maintain the parent fold by IgG se-
lection  and  subsequently  selected  against  Aβ1–40 (Figure 5). 
Several proteins were isolated, notably one of these small 
β-sheet  rich proteins, TJ10, maintained  its structure and was 
shown to inhibit Aβ1–40 aggregation in a stoichiometric manner. 
Initial dynamic light scattering experiments suggest that TJ10 
interacts and likely traps soluble oligomers of Aβ1–40 that range 
from 10–300 nm in diameter.
This approach has the potential for providing a structural 
handle on an Aβ1–40 binding protein motif not easily realizable 
with smaller unstructured peptides. The results from this selec-
tion also correlate well with the previously described selections 
with both antibodies and peptides, where aromatic residue 
rich sequences are strongly favored. From a molecular per-
spective this may suggest a possible common binding mode 
for Aβ where  aromatic  residues  in  suitable  protein  and  pep-
tide  scaffolds  interdigitate with  an  existing  core Aβ  structure. 
In many of the above cases, 
experiments need to be per-
formed to explore whether 
these  Aβ  selected  peptides 
and proteins also target mul-
tiple amyloidogenic proteins 
as observed in the case of 




In the past decade nu-
merous organic compounds 
have been studied for the in-
hibition of amyloid aggrega-
tion as a direct therapeutic 
strategy for the treatment of 
amyloidosis. These include 
surfactants,127 Cu/Zn chela-
tors,128 known bioactive mol-
ecules (for example, apo-
morphine,129 rifamycine,130 
curcumin,131 porphyrins,130), 
and sulfonated dyes such 
as Congo red and its de-
rivatives.132 In fact, Congo 
red was  the first small mole-
cule reported to bind to am-
yloid in tissue sections and 
exhibited the characteristic 
yellow-green birefringence 
under cross polarizers.133, 134 
Later  thioflavin T  (ThT)  and 
S (ThS) were also shown to 
characteristically stain am-
yloid deposits.135, 136 These 
two dyes are the classic re-
agents for determining char-
acteristic  β-sheet  mediated 
fibrillization  seen  for  all  am-
yloid forming proteins. It 
speaks to the difficulty  in the 
biophysical studies in this arena that the mode of interaction of 
these dyes with amyloid aggregates is still not clearly under-
stood, though solid-state NMR studies may soon establish a 
molecular description of these interactions. Many reports indi-




α/β and β  conformations.137 Analogous studies with ThT, the 
reagent of choice for following Aβ aggregation, need to be car-
ried out as many reports on Aβ inhibition are based on these 
assays. Congo red and ThT have also been shown to inhibit 
fibril  formation42, 138 at higher concentrations. Thus chemical 
derivatives of these dyes, with enhanced permeability through 
the blood-brain barrier, have been synthesized (Table 5) as 
in vivo imaging probes.139–141 Results from these ongoing 
studies may help in early diagnosis of AD.
Table 5. Chemical derivatives of Congo red and ThT used as imaging probes for detecting amyloid plaque.
 
Fluorogenic and radiolabeled derivatives of Congo red and ThT
 
* represents the atom radiolabeled.
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Not surprisingly perhaps, many reported small molecule in-
hibitors are similar to Congo Red and ThT, in that they are pla-
nar  and  aromatic.  The  possible  mode  of  interaction  with Aβ 
has been reviewed by Porat et al.142 It is also interesting to 
again note that many of the proteins and peptides selected to 
bind Aβ  also  contain  a  preponderance  of  aromatic  residues. 
It is tempting to speculate that both small molecules and aro-
matic amino acid residues can intercalate within grooves cre-
ated by β-sheets  in both the soluble oligomeric forms as well 
as the large fibrils.
Many studies with small molecules have focused on the 
inhibition  of  fibril  formation,  however  Blanchard  et al.  have 
screened a library of >3000 small molecules in an attempt to 
discover  compounds  that  reduce  the  β-sheet  content  of  pre-
formed  fibrils  of Aβ42.
143 Of the six lead compounds, 4,5-di-
anilinophthalimide (DAPH) was reported to effectively re-
duce  Aβ1–42  fibrils  when  incubated  with  preformed  Aβ1–42 
fibrils  in  equimolar  amounts  for  24 h.  However,  as  is  com-
mon to this field,  the authors utilized the standard ThT assay 
in their screens, where there is the possibility of unintention-
ally isolating small molecules that interfere with ThT binding 
rather  than  disaggregate  preformed  amyloid  fibers.  Experi-
ments have shown that many compounds (for example, mela-
tonin, β-cyclodextrin, phthalocyanine, dimethyl yellow, and fe-
nofibrate) competitively prevent the binding of ThT to the fibrils 
giving a possible  false positive with  regard  to  inhibition of Aβ 
aggregation.42 However, elegant work by Lockhart et al. has 
shown that Congo red-type molecules do not share the same 
binding site as ThT on fibrils.146, 147 Competition studies to de-
termine the binding preferences of small molecule inhibitors 
and these classic ligands should be performed before conclu-
sions regarding mechanisms of action are drawn.
With mounting evidence implicating soluble oligomeric in-
termediates as the toxic species, it is perhaps not sufficient to 
identify  small  molecule  drug  candidates  that  inhibit  fibrilliza-
tion but rather those that prevent toxicity. This is perhaps best 
exemplified  by  a  study  where  naphthalene  sulfonates  were 
shown  to  inhibit  fibril  formation  but  stabilized  the  toxic  oligo-
mers.148 In another example, the hydroxyaniline derivatives, 
RS-0406 (reported to inhibit aggregation)149 and RS-0466 
(reported to have no effect on aggregation)145 (Table 6) were 
shown  to  inhibit  the  formation of SDS-stable Aβ oligomers  in 
living cells.144
The most comprehensive effort in this area is a recent re-
port by Glabe and co-workers,42 where they systematically 
evaluated 40 previously reported small molecule Aβ inhibitors. 
This study attempts to clarify the role of the small molecule in-
hibitors in terms of their ability to interact with Aβ oligomers or 
fibrils or both. A battery of assays were utilized,  that  included 
ThT  fluorescence,  turbidimetry,  dot-blot/western  blot  assays 
with  oligomer  specific  antibodies  (A11),  and  TEM  to  under-
stand the aggregation kinetics and minimize the effect of any 
artifact related to a particular assay. Based on their results, 
Necula et al. categorized their screens into three classes: 
class I consisted of compounds that inhibited oligomerization 




The data suggest that it may be possible to selectively in-
hibit  “off-pathway”  intermediates  and/or  fibril  formation.  This 
study agrees quite well with a screen of small molecules 
against tau filament formation and Aβ1–40 aggregation reported 
by Taniguchi et al.130 A comparison of the IC50 values reported 
by the two groups showed very similar trends in inhibitory ac-
tivity and thus provides the field with a useful set of standard 
molecules (Figure 6). Interestingly, the A11 antibody is cross-
reactive with a wide variety of oligomeric species,118 indicating 
that inhibitors may have general applicability across many dif-
ferent aggregation diseases.
A clever approach combines small molecule targeting with 
natural bystander proteins to prevent amyloid aggregation.150 
Gestwicki et al. designed a bifunctional molecule by cova-
lently tethering a synthetic ligand (SLF) to Congo red (CR) 
(Figure 7 a).150  CR  at  one  end  interacts  with  aggregated Aβ 
whereas the synthetic ligand recruits a molecular chaperone 
(FKBP), providing the small molecule derivative with the nec-
essary  steric  bulk  to  disrupt  Aβ  aggregation.  This  approach 
significantly enhanced the potency of CR by several-fold (IC50 




Comparison of results for RS-0466 and RS-0406




   
RS-0466 and RS-0406 inhibited Aβ induced cytotoxicity in HeLa   Both compounds prevented formation of Aβ oligomers in 
cells and blocked impairment of long-term potentiation in rat   living cells (7A2 cells) and blocked Aβ-mediated LTP. 
hippocampal slices.  
   
How these compounds inhibited Aβ induced cytotoxicity was not   It was shown that RS-0466 and RS-0406 inhibited the formation 
studied.  of new oligomers, they did not affect preformed Aβ oligomers.
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treated neurons displayed normal morphology and high cell 
viability (~70 %). To further increase the potency of the biva-
lent inhibitor, the authors varied the linker length between SLF 
and CR. Of the three new molecules created (Figure 7 b), SLF-
Benz-CR/FKBP was most effective with an IC50 of 50 nM. The 
authors did observe the presence of small aggregates in elec-
trophoretic  analysis  and AFM  images  in Aβ  samples  treated 
with their bifunctional molecule.
Finally a screen has been developed for the discovery of 
Aβ  aggregation  inhibitors  in  E. coli cells.151 This approach 
takes advantage of a green fluorescent protein  (GFP) based 
assay152  where  the  fluorescence  of GFP  is  compromised  by 
attachment  of Aβ,  presumably  due  to  GFP-misfolding  medi-
ated by Aβ aggregation. GFP  folding and fluorescence  is  re-
covered upon treatment of the E. coli with small molecules that 
likely disrupt Aβ aggregation. This may be a useful approach 
for  the  rapid  screening  of  small  molecule  Aβ  inhibitors  and 
could eventually be used in more permeable mammalian cells.
Overall, the small molecule approach to Aβ aggregation in-
hibition is clearly poised to provide new and useful reagents 
for in vivo diagnostics as therapeutic applications are already 
being demonstrated for analogues of classic Aβ binders such 
as Congo Red and ThT. The existing small molecules are also 
being probed for their ability to interact with different amyloid 
species along the fibrillization pathway, which when correlated 
with cellular toxicity studies will likely provide useful protocols 
for evaluating new anti-Aβ molecules as they are identified.
Figure 6. A comparison of the IC50 values reported by Taniguchi 
et al.130 and Necula et al.42 for the inhibition of Aβ aggregation by small 
molecules.
Table 7. Small molecules categorized into classes based on their effect on Aβ1–42 aggregation42  (continued).
Class III (Compounds that inhibit fibrillization but do not inhibit oligomerization)
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Summary
In this review we have aimed 
to provide a comprehensive 
view of the rapidly growing mo-
lecular toolbox at our disposal 
for  targeting  Aβ.  We  have  de-
scribed a wide range of mole-
cules  that  target  Aβ,  including 
natural proteins, peptides, pep-
tidomimetics, and small mole-
cules. We have also described 
recent approaches for selec-
tions and screens for devel-
oping  Aβ  targeting  antibod-
ies, proteins, and peptides 
that have been shown to inter-
act  with  Aβ  oligomers  and  fi-
brils  and  influence  aggregation 
kinetics. These new strategies 
and the resulting molecules be-
ing discovered provide a start-
ing point for analogue synthe-
sis that should help in furthering 
our understanding of the mech-
anism  of  Aβ  aggregation  and 
ultimately aid in reducing cel-
lular toxicity. Moreover, many 
of these new approaches may 
be applied to other amyloido-
genic diseases. These mole-
cules provide new and inter-
esting design opportunities as 
seen in the case of the novel 
small molecule directed chaper-
ones. Opportunities clearly exist 
for utilizing the described small 
molecules and peptides discov-
ered to date for decorating dis-
crete multivalent dendrimers to 
provide new multivalent enti-
ties for targeting both oligomers 
and  fibrils.93, 153, 154 Thus with 
this growing toolbox in hand, 
new methods for the molecular 
design of diagnostic and ther-
apeutic agents will clearly be 
forthcoming.
Outlook
The study of the aggregation 
pathway of Aβ  is  a  difficult  and 
challenging endeavor and future 
work  in  targeting Aβ will neces-
sitate the development of sen-
sitive analytical methods that 
continue to clarify molecular 
mechanisms for the pathophys-
iology of Alzheimer’s disease. 
Furthermore, new biophysical 
studies must aim to correlate 
Figure 7. a)   Blocking Aβ  fibrillization  using  a  bifunctional  small molecule  that  binds  to FKBP  to  in-
crease the steric bulk of the molecule. b) Adding linkers into SLF-CR improves inhibition of aggrega-
tion and toxicity.
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in vivo toxicity with in vitro aggregation models to allow for ac-
curate interpretation of the mechanism of action of the mol-
ecules that are currently available. From a molecular design 
perspective, the many ligands that we have described should 
be amenable to further chemical functionalization with appro-
priate imaging agents to develop new and powerful in vitro and 
in vivo  assays  that  target  different  species  in  the  fibrillization 
pathway. This approach will allow for the development of mole-
cules that target specific Aβ assemblies and correlate them to 
disease outcomes. As an example, many of the reported small 
molecules that target oligomers and fibrils, will  likely be ame-
nable to radioisotope incorporation for in vivo diagnostic imag-
ing with PET (Positron Emission Tomography)155 and SPECT 
(Single Photon Emission Computerized Tomography).139, 156 
Thus at the current time we are clearly at the threshold of dis-
covering new diagnostic tools as well as therapeutic molecules 
that may help ameliorate the devastating neurological effects 
of Alzheimer’s disease.
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